Next Generation Pharmaceutical Cleanroom
Next Generation Pharmaceutical Cleanroom
6th October to 7th October 2021,
London, United Kingdom
SMi proudly presents the 2nd Annual Next Generation Pharmaceutical Cleanroom Conference being held in London on 6 - 7 October 2021.
It is a critical time for cleanrooms as new regulations in GMP enter their final drafts after several months in review. This conference will explore the forecasted impacts of the new regulations across the pharmaceutical cleanroom industry, from designer to operator.
These significant updates will be influential in the regulatory procedure across the cleanroom industry and come at a time when the global cleanroom technologies market is set to surpass GBP 3 billion in value.
This rapidly growing industry sustains an identical rate of evolution; technological leaps in airflow visualisation and environmental monitoring provide deeper insight into cleanroom management and contribute to the increasing standards in sterility. Additionally, the development of entirely new medicines is forcing new regulatory measures into play.
The agenda will look deeply into the influence of the developments in Annex 1, ISO 14644 and GMP compliance, as well as insights into the novel technologies surfacing in this industry, from robotics and automation to isolator technology implementation.
We look forward to welcoming you to the conference in October.
source: http://www.smi-online.co.uk/pharmaceuticals/uk/conference/cleanroom-technology
If you have any questions about this news, please do not hesitate to contact us.
Join Our Newsletter for Free
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE